Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity

Journal of Medicinal Chemistry

Volumn 55, Issue 1, 2012, Pages 475-488

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Salvador, Maria Kimatrai ^a   Preti, Delia ^a   Aghazadeh Tabrizi, Mojgan ^a   Brancale, Andrea ^b   Fu, Xian Hua ^c   Li, Jun ^c   Zhang, Su Zhan ^c   Hamel, Ernest ^e   Bortolozzi, Roberta ^b   Basso, Giuseppe ^d   Viola, Giampietro ^d  

^a UNIVERSITY OF FERRARA   (Italy)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c ZHEJIANG UNIVERSITY   (China)

^d UNIVERSITY OF PADOVA   (Italy)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4,5 TRIMETHOXYPHENYL) 5 (3,4 DIMETHOXYPHENYL) 1H; 1 (3,4,5 TRIMETHOXYPHENYL) 5 (4 ETHOXYPHENYL) 1H TETRAZOLE; 1 (3,4,5 TRIMETHOXYPHENYL) 5 (4 ETHYLPHENYL) 1H TETRAZOLE; 1 (3,4,5 TRIMETHOXYPHENYL) 5 (4 METHOXYPHENYL) 1H TETRAZOLE; 1 (3,4,5 TRIMETHOXYPHENYL) 5 (4 PROPOXYPHENYL) 1H TETRAZOLE; 1 (3,4,5 TRIMETHOXYPHENYL) 5 (THIOPHEN 2 YL) 1H TETRAZOL; 1 (3,4,5 TRIMETHOXYPHENYL) 5 [4 (PENTYLOXY)PHENYL] 1H TETRAZOLE; 1 (3,4,5 TRIMETHOXYPHENYL) 5 P TOLYL 1H TETRAZOLE; 1 (3,4,5 TRIMETHOXYPHENYL) 5 PHENYL 1H TETRAZOLE; 1 [4 [1 (3,4,5 TRIMETHOXYPHENYL) 1H TETRAZOL 5 YL]PHENYL]ETHANONE; 1,5 BIS(3,4,5 TRIMETHOXYPHENYL) 1H TETRAZOLE; 5 (3 CHLORO 4 ETHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL) 1H TETRAZOLE; 5 (3 CHLORO 4 METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL) 1H TETRAZOLE; 5 (3 FLUORO 4 METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL) 1H TETRAZOLE; 5 (3 METHYL 4 METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL) 1H TETRAZOLE; 5 (4 BUTOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL) 1H TETRAZOLE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; COMBRETASTATIN A4; GLYCOPROTEIN P; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL STRAIN HT29; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES; TRANSPLANTATION, HETEROLOGOUS; TUBULIN MODULATORS;

EID: 84862916801     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2013979     Document Type: Article

References (59)

1. Downing, K. H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics Annu. Rev. Cell Dev. Biol. 2000, 16, 89-111
2. Amos, L. A. Microtubule structure and its stabilisation Org. Biomol. Chem. 2004, 2, 2153-2160
3. Honore, S.; Pasquier, E.; Braguer, D. Understanding microtubule dynamics for improved cancer therapy Cell. Mol. Life Sci. 2005, 62, 3039-3056
4. Risinger, A. L.; Giles, F. J.; Mooberry, S. L. Microtubule dynamics as a target in oncology Cancer Treat. Rev. 2008, 35, 255-261
5. Kingston, D. G. Tubulin-interactive natural products as anticancer agents (1) J. Nat. Prod. 2009, 72, 507-515
6. Dumantet, C.; Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics Nat. Rev. Drug Discovery 2010, 9, 790-803
7. Kanthou, C.; Tozer, G. M. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies Int. J. Exp. Pathol. 2009, 90, 284-294
8. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experentia 1989, 45, 209-211
9. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin Biochemistry 1989, 28, 6984-6991
10. McGown, A. T.; Fox, B. W. Differential cytotoxicity of combretastatins A1 and A4 in two daunorubucin-resistant P388 cell lines Cancer Chemother. Pharmacol. 1990, 26, 79-81
11. Petit, I.; Karajannis, M. A.; Vincent, L.; Young, L.; Butler, J.; Hopper, A. T.; Shido, K.; Steller, H.; Chaplin, D. J.; Feldman, E.; Rafi, S. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death Blood 2008, 111, 1951-1961
12. Siemann, D. W.; Chaplin, D. J.; Walike, P. A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) Expert Opin. Invest. Drugs 2009, 18, 189-197
13. Patterson, D. M.; Rustin, G. J. S. Combretastatin A-4 phosphate Drugs Future 2007, 32, 1025-1032
14. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: present and future directions J. Med. Chem. 2006, 49, 3033-3044
15. Chaudari, A.; Pandeya, S. N.; Kumar, P.; Sharma, P. P.; Gupta, S.; Soni, N.; Verma, K. K.; Bhardwaj, G. Combretastain A-4 analogues as anticancer agents Mini-Rev. Med. Chem. 2007, 12, 1186-1205
16. Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical design of antimitotic agents based on combretastatins Curr. Pharm. Des. 2005, 11, 1655-1677
17. Mahindroo, N; Liou, J. P.; Chang, J. Y.; Hsieh, H. P. Antitubulin agents for the treatment of cancer. A medicinal chemistry update Expert Opin. Ther. Pat. 2006, 16, 647-691
18. Theeramunkong, S.; Caldarelli, A.; Massarotti, A.; Aprile, S.; Caprifoglio, D.; Zaninetti, R.; Teruggi, A.; Pirali, T.; Grosa, G.; Tron, G. C.; Genazzani, A. A. Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues J. Med. Chem. 2011, 54, 4977-4986
19. Ohsumi, K.; Hatanaka, T.; Fujita, K.; Nakagawa, R.; Fukuda, Y.; Nihai, Y.; Suga, Y.; Morinaga, Y.; Akiyama, Y.; Tsuji, T. Synthesis and antitumor activity of cis-restricted combretastatins 5-membered heterocyclic analogues Bioorg. Med. Chem. Lett. 1988, 8, 3153-3158
20. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; Hannick, S. M.; Gherke, L.; Credo, R. B.; Hui, Y.-H.; Marsh, K.; Warner, R.; Lee, J. Y.; Zielinski-Mozng, N.; Frost, D.; Rosenberg, S. H.; Sham, H. L. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmaokinetics, and in vivo antitumor activity evaluation J. Med. Chem. 2002, 45, 1697-1711
21. Bonezzi, K.; Taraboletti, G.; Borsotti, P.; Bellina, F.; Rossi, R.; Gavazzi, R. Vascular disrupting activity of tubulin-binding 1,5-diaryl-1 H -imidazoles J. Med. Chem. 2009, 52, 7906-7910
22. Schobert, R.; Biersack, B.; Dietrich, A.; Effenberger, K.; Knauer, S.; Mueller, T. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and N -methylimidazoles that are cytotoxic against combretastatin A-4 resistant tumor cels and vascular disrupting in a cis-platin resistant germ cell tumor model J. Med. Chem. 2010, 53, 6595-6002
23. Kaffy, J.; Pontikis, R.; Carrez, D.; Croisy, A.; Monneret, C.; Florent, J.-C. Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation Bioorg. Med. Chem. 2006, 14, 4067-4077
24. Lee, S.; Kim, J. N.; Lee, H. K.; Yoon, K. S.; Shin, K. D.; Kwon, B.-M.; Han, D. C. Biological evaluation of KRIBB3 analogs as a microtubule polymerization inhibitor Bioorg. Med. Chem. Lett. 2011, 21, 977-979
25. Wu, M.; Li, W.; Yang, C.; Chen, D.; Ding, J.; Chen, Y.; Lin, L.; Xie, Y. Synthesis and activity of combretastatin A-4 analogues: 1,2,3-thiadiazoles as potent antitumor agents Bioorg. Med. Chem. Lett. 2007, 17, 869-873
26. Odlo, K.; Hntzen, J.; Fournier dit Chabert, J.; Ducki, S.; Gani, O. A. B. S. M.; Sylte, I.; Skrede, M.; Florenes, V. A.; Hansen, T. V. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin Bioorg. Med. Chem. 2008, 16, 4829-4838
27. Zhang, Q.; Peng, Y.; Wang, X. I.; Keeman, S. M.; Aurora., S.; Welsh, W. J. Highly potent triazole-based tubulin polymerization inhibitors J. Med. Chem. 2007, 50, 749-754
28. Romagnoli, R.; Baraldi, P. G.; Cruz-Lopez, O.; Lopez-Cara, C.; Carrion, M. D.; Brancale, A.; Hamel, E.; Chen, L.; Bortolozzi, R.; Basso, G.; Viola, G. Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogs J. Med. Chem. 2010, 53, 4248-4258
29. Cushman, M.; Nagarathnam, D.; Gopal, D.; He, H.-M.; Lin, C. M.; Hamel, E. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5- trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents J. Med. Chem. 1992, 35, 2293-2306
30. Gaukroger, K.; Hadfield, J. A.; Lawrence, N. J.; Nlan, S.; McGown, A. T. Structural requirements for the interaction of combretastatins with tubulin: How important is the trimethoxy unit? Org. Biomol. Chem. 2003, 1, 3033-3037
31. For compound 7a see the following: Potewar, T. M.; Siddiqui, S. A.; Lahoti, R. J.; Srinivasan, K. V. Efficient and rapid synthesis of 1-substituted-1 H -1,2,3,4-tetrazoles in the acidic ionic liquid 1- n -butylimidazolium tetrafluoroborate Tetrahedron Lett. 2007, 48, 1721-1724
32. For compound 7b see the following: Vorobiov, A. N.; Gaponik, P. N.; Petrov, P. T.; Ivashkevich, O. A. One-pot syntheses of 5-amino-1-aryltetrazole derivatives Synthesis 2010, 1307-1312
33. Satoh, Y.; Marcopulos, N. Application of 5-lithiotetrazoles in organic synthesis Tetrahedron Lett. 1995, 36, 1679-1682
34. Yi, K. Y.; Yoo, S. Synthesis of 5-aryl and vinyl tetrazoles by the palladium-catalyzed cross-coupling reaction Tetrahedron Lett. 1995, 36, 1679-1682
35. Spulak, M.; Lubojacky, R.; Senel, P.; Kunes, J.; Pour, M. Direct C-H arylation and alkenylation of 1-substituted tetrazoles: phosphine as stabilizing factor J. Org. Chem. 2010, 75, 241-244
36. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin Cell Biochem. Biophys. 2003, 38, 1-21
37. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells Mol. Pharmacol. 1998, 53, 62-67
38. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery 2006, 5, 219-234
39. Baguley, B. C. Multidrug resistance mechanism in cancer Mol. Biotechnol. 2010, 46, 308-316
40. Dupuis, M.; Flego, M.; Molinari, A.; Cianfriglia, M. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEM rev cells HIV Med. 2003, 4, 338-345
41. Toffoli, G.; Viel, A.; Tuimoto, I.; Bisconti, G.; Rossi, G.; Baoiocchi, M. Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines Br. J. Cancer 1991, 63, 51-56
42. Martello, L. A.; Verdier-Pinard, P.; Shen, H. J.; He, L.; Torres, K.; Orr, G. A.; Horwitz, S. B. Elevated level of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation Cancer Res. 2003, 63, 448-454
43. Clarke, P. R.; Allan, L. A. Cell-cycle control in the face of damage: a matter of life or death Trends Cell Biol. 2009, 19, 89-98
44. Donzelli, M.; Draetta, G. F. Regulating mammalian checkpoints through Cdc25 inactivation EMBO Rep. 2003, 4, 671-677
45. Kiyokawa, H.; Ray, D. In vivo roles of Cdc25 phosphatases: biological insight into the anti-cancer therapeutic targets Anti-Cancer Agents Med. Chem. 2008, 8, 832-836
46. Vermes, I.; Haanen, C.; Steffens-Nakken, H.; Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V J. Immunol. Methods 1995, 184, 39-51
47. m) in apoptosis: an update Apoptosis 2003, 3, 115-128
48. Green, D. R.; Kroemer, G. The pathophysiology of mitochondrial cell death Science 2005, 305, 626-629
49. Cai, J.; Jones, D. P. Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss J. Biol. Chem. 1998, 273, 11401-11404
50. Rothe, G.; Valet, G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′- dichlorofluorescein J. Leukocyte Biol. 1990, 47, 440-448
51. Nohl, H.; Gille, L.; Staniek, K. Intracellular generation of reactive oxygen species by mitochondria Biochem. Pharmacol. 2005, 69, 719-723
52. Denault, J.-B.; Salvesen, G. S. Caspases: keys in the ignition of cell death Chem. Rev. 2002, 102, 4489-4499
53. Porter, A. G.; Janicke, R. U. Emerging role of caspase-3 in apoptosis Cell Death Differ. 1999, 6, 99-104
54. Mollinedo, F.; Gajate, C. Microtubules, microtubule-interfering agents and apoptosis Apoptosis 2003, 8, 413-450
55. Dingemans, T.; Photinos, D. J.; Samulski, E. T.; Terzis, A. F.; Wutz, C. Ordering of apolar and polar solutes in nematic solvents J. Chem. Phys. 2003, 118, 7046-7061
56. Viola, G.; Fortunato, E.; Cecconet, L.; Del Giudice, L.; DallAcqua, F.; Basso, G. Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544 Toxicol. Appl. Pharmacol. 2008, 227, 84-96
57. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 2004, 428, 198-202
58. Molecular Operating Environment (MOE 2008.10); Chemical Computing Group, Inc.: Montreal, Quebec, Canada; http://www.chemcomp.com.
59. Korb, O.; Stötzle, T.; Exner, T. E. PLANTS: Application of Ant Colony Optimization to Structure-Based Drug Design. In Ant Colony Optimization and Swarm Intelligence, 5th International Workshop, ANTS 2006, Brussels, Belgium, Sep 4-7, 2006; Dorigo, M.; Gambardella, L. M.; Birattari, M.; Martinoli, A.; Poli, R.; Sttzle, T., Eds.; Springer: Berlin, Germany, 2006; LNCS 4150, pp 247-258.